Timing and causes of death in severe COVID-19 patients

[1] Guan W(2020)Clinical characteristics of coronavirus disease 2019 in China N Engl J Med 382 1708-1720

[2] Ni Z(2020)Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area JAMA 25 79-2344

[3] Hu Y(2020)Causes and circumstances of death among patients hospitalized with COVID-19: a retrospective cohort study Ann ATS 383 2333-2533

[4] Richardson S(2021)Causes and timing of death in critically ill COVID-19 patients Crit Care 307 2526-868

[5] Hirsch JS(2020)Efficacy of Tocilizumab in patients hospitalized with Covid-19 New Engl J Med 14 865-281

[6] Narasimhan M(2020)Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ 28 261-645

[7] Ketcham SW(2012)Acute respiratory distress syndrome: the Berlin definition JAMA 299 637-948

[8] Bolig T(2020)Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2 Expert Rev Respir Med 159 933-810

[9] Molling DJ(2019)Pneumonies associées aux soins de réanimation* RFE commune SFAR–SRLF Méd Intensive Réa 315 801-432

[10] Contou D(2008)Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial JAMA 8 430-186

[1] Guan W(2020)Clinical characteristics of coronavirus disease 2019 in China N Engl J Med 382 1708-1720

[2] Ni Z(2020)Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area JAMA 25 79-2344

[3] Hu Y(2020)Causes and circumstances of death among patients hospitalized with COVID-19: a retrospective cohort study Ann ATS 383 2333-2533

[4] Richardson S(2021)Causes and timing of death in critically ill COVID-19 patients Crit Care 307 2526-868

[5] Hirsch JS(2020)Efficacy of Tocilizumab in patients hospitalized with Covid-19 New Engl J Med 14 865-281

[6] Narasimhan M(2020)Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ 28 261-645

[7] Ketcham SW(2012)Acute respiratory distress syndrome: the Berlin definition JAMA 299 637-948

[8] Bolig T(2020)Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2 Expert Rev Respir Med 159 933-810

[9] Molling DJ(2019)Pneumonies associées aux soins de réanimation* RFE commune SFAR–SRLF Méd Intensive Réa 315 801-432

[10] Contou D(2008)Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial JAMA 8 430-186